Journal
ASIAN JOURNAL OF UROLOGY
Volume 3, Issue 4, Pages 286-292Publisher
ELSEVIER SINGAPORE PTE LTD
DOI: 10.1016/j.ajur.2016.08.006
Keywords
Renal cell carcinoma; Metastasis; Vascular endothelial growth factor; Mammalian target of rapamycin; Hypoxia inducible factor
Categories
Funding
- Pfizer
- Novartis
- Aveo
- Genentech
- Exelixis
- BMS
- Astellas
- GSK
Ask authors/readers for more resources
Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns of metastasis in RCC and how distinct systemic therapy approaches may be considered based on the anatomic location of metastasis. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available